董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erez Aminov | 男 | Chairman of the Board and Chief Executive Officer and Director | 48 | 530.42万美元 | 919.67 | 2026-09-11 |
| Matthew Pratt Whalen | 男 | Director | 46 | 1.65万美元 | 2.50 | 2026-09-11 |
| Matthew Paul Del Giudice | 男 | Director | 44 | 6.98万美元 | 7.50 | 2026-09-11 |
| Edward MacPherson | 男 | Director | 37 | 6.98万美元 | 7.50 | 2026-09-11 |
| Denil Nanji Shekhat | 男 | Director | 45 | 11.74万美元 | 15.00 | 2026-09-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erez Aminov | 男 | Chairman of the Board and Chief Executive Officer and Director | 48 | 530.42万美元 | 919.67 | 2026-09-11 |
| Andriy Mushak | 男 | Chief Financial Officer | 43 | 未披露 | 未持股 | 2026-09-11 |
| Andriy Mushak | 男 | Chief Financial Officer | 43 | 未披露 | 未持股 | 2026-09-11 |
董事简历
中英对照 | 中文 | 英文- Erez Aminov
-
埃雷兹阿米诺夫，自2023年4月起担任Mira Pharmaceuticals，Inc.董事兼首席执行官。从2022年4月至2023年3月，Aminov先生是Mira Pharmaceuticals，Inc.公司的顾问，在筹资和投资者关系事务方面提供支持。Aminov先生是一位经验丰富的生物技术投资者和顾问，拥有超过18年的经验。自2021年9月以来，Aminov先生是战略和投资咨询公司Locate Venture Corp的创始人，该公司为多家处于早期阶段的生命科学公司提供咨询，包括MyMD Pharmaceuticals（纳斯达克：MYMD）、Telomir Pharmaceuticals和Tyna Pharmaceuticals的筹资和战略合作。Aminov先生的工作主要集中在协助客户构建私人投资机会、设计新的临床合作伙伴关系以及谈判进入新市场的机会。2015年2月至2020年9月，Aminov先生担任电子产品和游戏产品全球分销商Finds4less Inc.的总裁。在担任这一职务期间，Aminov先生为公司运营的各个方面提供战略监督和指导，同时还领导新的业务发展计划，以利用新兴市场的机会。Aminov先生于2004年在纽约图罗大学获得会计学学士学位。
Erez Aminov has served as a director and Mira Pharmaceuticals, Inc.'s Chief Executive Officer since April 2023 and as Mira Pharmaceuticals, Inc.'s Chairman since March 2024. Mr. Aminov is an experienced biotechnology consultant and investor and initially joined the company as a consultant in 2022. Mr. Aminov's experience in the biotech consulting sector began in 2021 when he founded Locate Venture Corp. in September 2021. Locate Venture is a strategy and investment consulting firm focused on advancing and supporting early stage biotech startups. Prior to founding Locate Venture Corp., from February 2015 to September 2020, Mr. Aminov served as the President of Finds4less Inc., a global distributor of electronics and gaming products. In this role, Mr. Aminov provided strategic oversight and direction for all aspects of the company's operations, while also spearheading new business development initiatives to capitalize on emerging market opportunities. Mr. Aminov's more than two decades of experience includes experience with the biotech industry's particular challenges, including creating strategic alliances and guiding startups toward growth and prosperity. Mr. Aminov earned a B.A. in Accounting from Touro University in New York. - 埃雷兹阿米诺夫，自2023年4月起担任Mira Pharmaceuticals，Inc.董事兼首席执行官。从2022年4月至2023年3月，Aminov先生是Mira Pharmaceuticals，Inc.公司的顾问，在筹资和投资者关系事务方面提供支持。Aminov先生是一位经验丰富的生物技术投资者和顾问，拥有超过18年的经验。自2021年9月以来，Aminov先生是战略和投资咨询公司Locate Venture Corp的创始人，该公司为多家处于早期阶段的生命科学公司提供咨询，包括MyMD Pharmaceuticals（纳斯达克：MYMD）、Telomir Pharmaceuticals和Tyna Pharmaceuticals的筹资和战略合作。Aminov先生的工作主要集中在协助客户构建私人投资机会、设计新的临床合作伙伴关系以及谈判进入新市场的机会。2015年2月至2020年9月，Aminov先生担任电子产品和游戏产品全球分销商Finds4less Inc.的总裁。在担任这一职务期间，Aminov先生为公司运营的各个方面提供战略监督和指导，同时还领导新的业务发展计划，以利用新兴市场的机会。Aminov先生于2004年在纽约图罗大学获得会计学学士学位。
- Erez Aminov has served as a director and Mira Pharmaceuticals, Inc.'s Chief Executive Officer since April 2023 and as Mira Pharmaceuticals, Inc.'s Chairman since March 2024. Mr. Aminov is an experienced biotechnology consultant and investor and initially joined the company as a consultant in 2022. Mr. Aminov's experience in the biotech consulting sector began in 2021 when he founded Locate Venture Corp. in September 2021. Locate Venture is a strategy and investment consulting firm focused on advancing and supporting early stage biotech startups. Prior to founding Locate Venture Corp., from February 2015 to September 2020, Mr. Aminov served as the President of Finds4less Inc., a global distributor of electronics and gaming products. In this role, Mr. Aminov provided strategic oversight and direction for all aspects of the company's operations, while also spearheading new business development initiatives to capitalize on emerging market opportunities. Mr. Aminov's more than two decades of experience includes experience with the biotech industry's particular challenges, including creating strategic alliances and guiding startups toward growth and prosperity. Mr. Aminov earned a B.A. in Accounting from Touro University in New York.
- Matthew Pratt Whalen
-
Matthew Pratt Whalen是施乐 Corporation的子公司MRC Smart Technology Solutions的首席财务官，在那里他在增加公司收入方面发挥了关键作用，并管理着跨多个部门的多元化团队。Whalen先生拥有圣地亚哥大学会计学学士学位，是加利福尼亚州的注册会计师。Whalen先生还曾在United Way San Diego的财务委员会任职。我们认为，基于Whalen先生在财务方面的丰富经验以及作为一名注册会计师，他有资格担任Telomir Pharmaceuticals，Inc.的董事之一。Whalen先生还曾担任MIRA Pharmaceuticals，Inc.（纳斯达克：MIRA）的董事。
Matthew Pratt Whalen is a Certified Public Accountant with over two decades of experience in public accounting and corporate finance. Mr. Whalen currently serves as the Chief Financial Officer of Power Digital Marketing Inc., an industry leading digital marketing agency, where he has driven significant revenue growth and led key financial transactions. Specifically, Mr. Whalen oversees the finance team, manages tax and audit relationships, and handles treasury management. Prior to joining Power Digital, from 2010 to May 2021, Mr. Whalen was the Chief Financial Officer of MRC Smart Technology Solutions, a subsidiary of Xerox Corporation where he played a pivotal role in growing the company's revenue and managed diverse teams across multiple departments. Mr. Whalen holds a B.A. in Accounting from the University of San Diego and is a Certified Public Accountant in California. Mr. Whalen has also served on the Finance Committee of United Way San Diego. - Matthew Pratt Whalen是施乐 Corporation的子公司MRC Smart Technology Solutions的首席财务官，在那里他在增加公司收入方面发挥了关键作用，并管理着跨多个部门的多元化团队。Whalen先生拥有圣地亚哥大学会计学学士学位，是加利福尼亚州的注册会计师。Whalen先生还曾在United Way San Diego的财务委员会任职。我们认为，基于Whalen先生在财务方面的丰富经验以及作为一名注册会计师，他有资格担任Telomir Pharmaceuticals，Inc.的董事之一。Whalen先生还曾担任MIRA Pharmaceuticals，Inc.（纳斯达克：MIRA）的董事。
- Matthew Pratt Whalen is a Certified Public Accountant with over two decades of experience in public accounting and corporate finance. Mr. Whalen currently serves as the Chief Financial Officer of Power Digital Marketing Inc., an industry leading digital marketing agency, where he has driven significant revenue growth and led key financial transactions. Specifically, Mr. Whalen oversees the finance team, manages tax and audit relationships, and handles treasury management. Prior to joining Power Digital, from 2010 to May 2021, Mr. Whalen was the Chief Financial Officer of MRC Smart Technology Solutions, a subsidiary of Xerox Corporation where he played a pivotal role in growing the company's revenue and managed diverse teams across multiple departments. Mr. Whalen holds a B.A. in Accounting from the University of San Diego and is a Certified Public Accountant in California. Mr. Whalen has also served on the Finance Committee of United Way San Diego.
- Matthew Paul Del Giudice
-
Matthew Paul Del Giudice，是佛罗里达州莱克兰市放射学和影像学专家的一名普通放射科医生。2015年7月至2021年2月，Del Giudice博士是Radiology Partners Phoenix的放射科医生，2014年7月至2015年6月，他在亚利桑那大学Health Sciences中心–图森担任肌肉骨骼放射科医生。Del Giudice博士获得了伊利诺伊大学厄巴纳-香槟分校的学士学位、洛约拉大学斯特里奇医学院的医学博士学位、洛约拉大学医学中心的放射学住院医师学位以及亚利桑那大学Health Sciences中心–图森的肌肉骨骼放射学研究金。Del Giudice医生获得了在佛罗里达州和俄亥俄州行医的许可。Del Giudice博士还担任MIRA Pharmaceuticals，Inc.（纳斯达克：MIRA）的董事。
Matthew Paul Del Giudice joined Mira Pharmaceuticals, Inc.'s company as a director in March 2024. Dr. Del Giudice has practiced as a radiologist since 2014. He currently serves as a general overnight emergency radiologist at the Cleveland Clinic and as a real estate investor with Comfort Living, LLC. Prior to joining the Cleveland Clinic, from March 2021 to May 2022, Dr. Del Giudice was a general radiologist with Radiology and Imaging Specialists in Lakeland, Florida. From July 2015 to February 2021, Dr. Del Giudice was a radiologist with Radiology Partners Phoenix, and from July 2014 to June 2015, he practiced as a musculoskeletal radiologist at the University of Arizona Health Sciences Center Tucson. Dr. Del Giudice received his B.S. from the University of Illinois at Urbana Champaign, his M.D. from Loyola University Stritch School of Medicine, completed his radiology residency at Loyola University Medical Center, and his musculoskeletal radiology fellowship at the University of Arizona Health Sciences Center Tucson. Dr. Del Giudice is licensed to practice medicine in Florida and Ohio. Dr. Del Giudice also serves as a director of Telomir Pharmaceuticals, Inc. (Nasdaq TELO). - Matthew Paul Del Giudice，是佛罗里达州莱克兰市放射学和影像学专家的一名普通放射科医生。2015年7月至2021年2月，Del Giudice博士是Radiology Partners Phoenix的放射科医生，2014年7月至2015年6月，他在亚利桑那大学Health Sciences中心–图森担任肌肉骨骼放射科医生。Del Giudice博士获得了伊利诺伊大学厄巴纳-香槟分校的学士学位、洛约拉大学斯特里奇医学院的医学博士学位、洛约拉大学医学中心的放射学住院医师学位以及亚利桑那大学Health Sciences中心–图森的肌肉骨骼放射学研究金。Del Giudice医生获得了在佛罗里达州和俄亥俄州行医的许可。Del Giudice博士还担任MIRA Pharmaceuticals，Inc.（纳斯达克：MIRA）的董事。
- Matthew Paul Del Giudice joined Mira Pharmaceuticals, Inc.'s company as a director in March 2024. Dr. Del Giudice has practiced as a radiologist since 2014. He currently serves as a general overnight emergency radiologist at the Cleveland Clinic and as a real estate investor with Comfort Living, LLC. Prior to joining the Cleveland Clinic, from March 2021 to May 2022, Dr. Del Giudice was a general radiologist with Radiology and Imaging Specialists in Lakeland, Florida. From July 2015 to February 2021, Dr. Del Giudice was a radiologist with Radiology Partners Phoenix, and from July 2014 to June 2015, he practiced as a musculoskeletal radiologist at the University of Arizona Health Sciences Center Tucson. Dr. Del Giudice received his B.S. from the University of Illinois at Urbana Champaign, his M.D. from Loyola University Stritch School of Medicine, completed his radiology residency at Loyola University Medical Center, and his musculoskeletal radiology fellowship at the University of Arizona Health Sciences Center Tucson. Dr. Del Giudice is licensed to practice medicine in Florida and Ohio. Dr. Del Giudice also serves as a director of Telomir Pharmaceuticals, Inc. (Nasdaq TELO).
- Edward MacPherson
-
Edward MacPherson，曾在太阳镜制造商Prive Revaux（2018年3月至2020年4月）、精选膳食公司Menud（2014年10月至2018年4月）以及健康和保健产品分销商Rejuvenetics，LLC（2012年12月至2016年3月）担任高级营销和领导职务。MacPherson先生拥有葛底斯堡学院经济学学士学位。MacPherson先生还担任MIRA Pharmaceuticals，Inc.（纳斯达克：MIRA）的董事。
Edward MacPherson joined Mira Pharmaceuticals, Inc.'s company as a director in March 2024. Mr. MacPherson currently serves as Chief Growth Officer for Power Digital, an industry leading digital marketing agency. Prior to joining Power Digital, from May 2016 to December 2023, he served as CEO and Head of Growth for Endrock Growth & Analytics, a company he founded and sold to Power Digital. Prior to founding Endrock Growth & Analytics, Mr. MacPherson held senior marketing and leadership positions at sunglass maker Prive Revaux (March 2018 to April 2020), curated meal company Menud (October 2014 to April 2018) and Rejuvenetics, LLC, a distributor of health and wellness products (December 2012 to March 2016). Mr. MacPherson holds a BA in Economics from Gettysburg College. Mr. MacPherson also serves as a director of Telomir Pharmaceuticals, Inc. (Nasdaq TELO). - Edward MacPherson，曾在太阳镜制造商Prive Revaux（2018年3月至2020年4月）、精选膳食公司Menud（2014年10月至2018年4月）以及健康和保健产品分销商Rejuvenetics，LLC（2012年12月至2016年3月）担任高级营销和领导职务。MacPherson先生拥有葛底斯堡学院经济学学士学位。MacPherson先生还担任MIRA Pharmaceuticals，Inc.（纳斯达克：MIRA）的董事。
- Edward MacPherson joined Mira Pharmaceuticals, Inc.'s company as a director in March 2024. Mr. MacPherson currently serves as Chief Growth Officer for Power Digital, an industry leading digital marketing agency. Prior to joining Power Digital, from May 2016 to December 2023, he served as CEO and Head of Growth for Endrock Growth & Analytics, a company he founded and sold to Power Digital. Prior to founding Endrock Growth & Analytics, Mr. MacPherson held senior marketing and leadership positions at sunglass maker Prive Revaux (March 2018 to April 2020), curated meal company Menud (October 2014 to April 2018) and Rejuvenetics, LLC, a distributor of health and wellness products (December 2012 to March 2016). Mr. MacPherson holds a BA in Economics from Gettysburg College. Mr. MacPherson also serves as a director of Telomir Pharmaceuticals, Inc. (Nasdaq TELO).
- Denil Nanji Shekhat
-
Denil Nanji Shekhat于2024年3月加入Mira Pharmaceuticals，Inc.的公司担任董事。Shekhat博士自2014年以来一直从事放射科医生的工作，目前在佛罗里达州惠灵顿的DNS远程放射科执业。在开始DNS远程放射学之前，Shekhat博士在2018年7月至2023年12月期间担任佛罗里达州放射学协会/放射学合作伙伴的肌肉骨骼专家。2015年7月至2018年8月，Shekhat博士在Bethesda Radiology Associates担任普通和肌肉骨骼放射科医生。Shekhat博士在鲍登学院获得经济学学士学位，在田纳西大学健康科学中心医学院获得医学博士学位，在浸信会纪念医院完成放射学住院医师实习，并在亚利桑那大学完成肌肉骨骼放射学研究金。Shekhat医生目前在佛罗里达州获得行医许可。
Denil Nanji Shekhat joined Mira Pharmaceuticals, Inc.'s company as a director in March 2024. Dr. Shekhat has practiced as a radiologist since 2014 and currently practices at DNS Teleradiology in Wellington, Florida. Prior to starting DNS Teleradiology, Dr. Shekhat was a musculoskeletal specialist for Radiology Associates of Florida/ Radiology Partners from July 2018 to December 2023. From July 2015 to August 2018, Dr. Shekhat practiced as a general and musculoskeletal radiologist with Bethesda Radiology Associates. Dr. Shekhat received his B.A. in economics from Bowdoin College, his M.D. from the University of Tennessee Health Science Center, College of Medicine, completed his radiology residency at Baptist Memorial Hospital and his musculoskeletal radiology fellowship at the University of Arizona. Dr. Shekhat is currently licensed to practice medicine in Florida. - Denil Nanji Shekhat于2024年3月加入Mira Pharmaceuticals，Inc.的公司担任董事。Shekhat博士自2014年以来一直从事放射科医生的工作，目前在佛罗里达州惠灵顿的DNS远程放射科执业。在开始DNS远程放射学之前，Shekhat博士在2018年7月至2023年12月期间担任佛罗里达州放射学协会/放射学合作伙伴的肌肉骨骼专家。2015年7月至2018年8月，Shekhat博士在Bethesda Radiology Associates担任普通和肌肉骨骼放射科医生。Shekhat博士在鲍登学院获得经济学学士学位，在田纳西大学健康科学中心医学院获得医学博士学位，在浸信会纪念医院完成放射学住院医师实习，并在亚利桑那大学完成肌肉骨骼放射学研究金。Shekhat医生目前在佛罗里达州获得行医许可。
- Denil Nanji Shekhat joined Mira Pharmaceuticals, Inc.'s company as a director in March 2024. Dr. Shekhat has practiced as a radiologist since 2014 and currently practices at DNS Teleradiology in Wellington, Florida. Prior to starting DNS Teleradiology, Dr. Shekhat was a musculoskeletal specialist for Radiology Associates of Florida/ Radiology Partners from July 2018 to December 2023. From July 2015 to August 2018, Dr. Shekhat practiced as a general and musculoskeletal radiologist with Bethesda Radiology Associates. Dr. Shekhat received his B.A. in economics from Bowdoin College, his M.D. from the University of Tennessee Health Science Center, College of Medicine, completed his radiology residency at Baptist Memorial Hospital and his musculoskeletal radiology fellowship at the University of Arizona. Dr. Shekhat is currently licensed to practice medicine in Florida.
高管简历
中英对照 | 中文 | 英文- Erez Aminov
埃雷兹阿米诺夫，自2023年4月起担任Mira Pharmaceuticals，Inc.董事兼首席执行官。从2022年4月至2023年3月，Aminov先生是Mira Pharmaceuticals，Inc.公司的顾问，在筹资和投资者关系事务方面提供支持。Aminov先生是一位经验丰富的生物技术投资者和顾问，拥有超过18年的经验。自2021年9月以来，Aminov先生是战略和投资咨询公司Locate Venture Corp的创始人，该公司为多家处于早期阶段的生命科学公司提供咨询，包括MyMD Pharmaceuticals（纳斯达克：MYMD）、Telomir Pharmaceuticals和Tyna Pharmaceuticals的筹资和战略合作。Aminov先生的工作主要集中在协助客户构建私人投资机会、设计新的临床合作伙伴关系以及谈判进入新市场的机会。2015年2月至2020年9月，Aminov先生担任电子产品和游戏产品全球分销商Finds4less Inc.的总裁。在担任这一职务期间，Aminov先生为公司运营的各个方面提供战略监督和指导，同时还领导新的业务发展计划，以利用新兴市场的机会。Aminov先生于2004年在纽约图罗大学获得会计学学士学位。
Erez Aminov has served as a director and Mira Pharmaceuticals, Inc.'s Chief Executive Officer since April 2023 and as Mira Pharmaceuticals, Inc.'s Chairman since March 2024. Mr. Aminov is an experienced biotechnology consultant and investor and initially joined the company as a consultant in 2022. Mr. Aminov's experience in the biotech consulting sector began in 2021 when he founded Locate Venture Corp. in September 2021. Locate Venture is a strategy and investment consulting firm focused on advancing and supporting early stage biotech startups. Prior to founding Locate Venture Corp., from February 2015 to September 2020, Mr. Aminov served as the President of Finds4less Inc., a global distributor of electronics and gaming products. In this role, Mr. Aminov provided strategic oversight and direction for all aspects of the company's operations, while also spearheading new business development initiatives to capitalize on emerging market opportunities. Mr. Aminov's more than two decades of experience includes experience with the biotech industry's particular challenges, including creating strategic alliances and guiding startups toward growth and prosperity. Mr. Aminov earned a B.A. in Accounting from Touro University in New York.- 埃雷兹阿米诺夫，自2023年4月起担任Mira Pharmaceuticals，Inc.董事兼首席执行官。从2022年4月至2023年3月，Aminov先生是Mira Pharmaceuticals，Inc.公司的顾问，在筹资和投资者关系事务方面提供支持。Aminov先生是一位经验丰富的生物技术投资者和顾问，拥有超过18年的经验。自2021年9月以来，Aminov先生是战略和投资咨询公司Locate Venture Corp的创始人，该公司为多家处于早期阶段的生命科学公司提供咨询，包括MyMD Pharmaceuticals（纳斯达克：MYMD）、Telomir Pharmaceuticals和Tyna Pharmaceuticals的筹资和战略合作。Aminov先生的工作主要集中在协助客户构建私人投资机会、设计新的临床合作伙伴关系以及谈判进入新市场的机会。2015年2月至2020年9月，Aminov先生担任电子产品和游戏产品全球分销商Finds4less Inc.的总裁。在担任这一职务期间，Aminov先生为公司运营的各个方面提供战略监督和指导，同时还领导新的业务发展计划，以利用新兴市场的机会。Aminov先生于2004年在纽约图罗大学获得会计学学士学位。
- Erez Aminov has served as a director and Mira Pharmaceuticals, Inc.'s Chief Executive Officer since April 2023 and as Mira Pharmaceuticals, Inc.'s Chairman since March 2024. Mr. Aminov is an experienced biotechnology consultant and investor and initially joined the company as a consultant in 2022. Mr. Aminov's experience in the biotech consulting sector began in 2021 when he founded Locate Venture Corp. in September 2021. Locate Venture is a strategy and investment consulting firm focused on advancing and supporting early stage biotech startups. Prior to founding Locate Venture Corp., from February 2015 to September 2020, Mr. Aminov served as the President of Finds4less Inc., a global distributor of electronics and gaming products. In this role, Mr. Aminov provided strategic oversight and direction for all aspects of the company's operations, while also spearheading new business development initiatives to capitalize on emerging market opportunities. Mr. Aminov's more than two decades of experience includes experience with the biotech industry's particular challenges, including creating strategic alliances and guiding startups toward growth and prosperity. Mr. Aminov earned a B.A. in Accounting from Touro University in New York.
- Andriy Mushak
Andriy Mushak是一位在马萨诸塞州联邦获得许可的有成就的注册会计师，在SEC报告、会计合规和财务报表审计方面拥有超过20年的经验。Mushak先生目前担任LMAM Consulting Group，LLC（“LMAM”）的合伙人，该公司是一家专业服务公司，在德克萨斯州达拉斯和马萨诸塞州波士顿设有办事处，专门从事SEC财务报告、技术会计和并购交易支持。在LMAM，Mushak先生领导SEC报告业务、财务报表编制以及为科技、生命科学、媒体、医疗用品、金融和制造业等不同行业的上市公司和私营公司提供咨询服务。在2025年共同创立LMAM之前，Mushak先生曾在Baker Tilly US，LLP（Boston）的审计业务部门任职十多年，最近担任高级经理，领导财务报表审计工作，并为公开交易和私人持有的客户提供鉴证和咨询服务。Mushak先生在Buchach管理和审计学院获得会计和审计理学硕士学位和经济学文学学士学位。Mushak先生是马萨诸塞州公共会计委员会许可的注册会计师。
Andriy Mushak is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC ("LMAM"), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.- Andriy Mushak是一位在马萨诸塞州联邦获得许可的有成就的注册会计师，在SEC报告、会计合规和财务报表审计方面拥有超过20年的经验。Mushak先生目前担任LMAM Consulting Group，LLC（“LMAM”）的合伙人，该公司是一家专业服务公司，在德克萨斯州达拉斯和马萨诸塞州波士顿设有办事处，专门从事SEC财务报告、技术会计和并购交易支持。在LMAM，Mushak先生领导SEC报告业务、财务报表编制以及为科技、生命科学、媒体、医疗用品、金融和制造业等不同行业的上市公司和私营公司提供咨询服务。在2025年共同创立LMAM之前，Mushak先生曾在Baker Tilly US，LLP（Boston）的审计业务部门任职十多年，最近担任高级经理，领导财务报表审计工作，并为公开交易和私人持有的客户提供鉴证和咨询服务。Mushak先生在Buchach管理和审计学院获得会计和审计理学硕士学位和经济学文学学士学位。Mushak先生是马萨诸塞州公共会计委员会许可的注册会计师。
- Andriy Mushak is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC ("LMAM"), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.
- Andriy Mushak
Andriy Mushak是一位在马萨诸塞州联邦获得许可的有成就的注册会计师，在SEC报告、会计合规和财务报表审计方面拥有超过20年的经验。Mushak先生目前担任LMAM Consulting Group，LLC（“LMAM”）的合伙人，该公司是一家专业服务公司，在德克萨斯州达拉斯和马萨诸塞州波士顿设有办事处，专门从事SEC财务报告、技术会计和并购交易支持。在LMAM，Mushak先生领导SEC报告业务、财务报表编制以及为科技、生命科学、媒体、医疗用品、金融和制造业等不同行业的上市公司和私营公司提供咨询服务。在2025年共同创立LMAM之前，Mushak先生曾在Baker Tilly US，LLP（Boston）的审计部门任职十多年，最近担任高级经理，领导财务报表审计工作，并为公开交易和私人持有的客户提供鉴证和咨询服务。Mushak先生在Buchach管理和审计学院获得了会计和审计理学硕士学位和经济学文学学士学位。Mushak先生是马萨诸塞州公共会计委员会许可的注册会计师。
Andriy Mushak is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC ("LMAM"), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.- Andriy Mushak是一位在马萨诸塞州联邦获得许可的有成就的注册会计师，在SEC报告、会计合规和财务报表审计方面拥有超过20年的经验。Mushak先生目前担任LMAM Consulting Group，LLC（“LMAM”）的合伙人，该公司是一家专业服务公司，在德克萨斯州达拉斯和马萨诸塞州波士顿设有办事处，专门从事SEC财务报告、技术会计和并购交易支持。在LMAM，Mushak先生领导SEC报告业务、财务报表编制以及为科技、生命科学、媒体、医疗用品、金融和制造业等不同行业的上市公司和私营公司提供咨询服务。在2025年共同创立LMAM之前，Mushak先生曾在Baker Tilly US，LLP（Boston）的审计部门任职十多年，最近担任高级经理，领导财务报表审计工作，并为公开交易和私人持有的客户提供鉴证和咨询服务。Mushak先生在Buchach管理和审计学院获得了会计和审计理学硕士学位和经济学文学学士学位。Mushak先生是马萨诸塞州公共会计委员会许可的注册会计师。
- Andriy Mushak is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC ("LMAM"), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support. At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing. Prior to co founding LMAM in 2025, Mr. Mushak served in the Audit practice at Baker Tilly US, LLP (Boston) for over a decade, most recently as a Senior Manager, where he led financial statement audits and provided assurance and advisory services for publicly traded and privately held clients. Mr. Mushak earned a Master of Science in Accounting and Auditing and a Bachelor of Arts in Economics from Buchach Institute of Management and Audit. Mr. Mushak is a Certified Public Accountant licensed by the Massachusetts Board of Public Accountancy.